What Is Inaxaplin?
Inaxaplin is an investigational drug currently being studied in clinical trials. It is being developed as an oral medication, administered in tablet form. As an investigational drug, Inaxaplin has not yet been approved by regulatory bodies like the FDA for any medical use. Its precise mechanism of action, or how it works in the body, is part of ongoing research, aiming to understand its potential therapeutic effects.
The primary focus of current research for Inaxaplin is on its potential to treat Proteinuric Kidney Disease. This condition is characterized by the presence of excess protein in the urine, which is a sign of kidney damage and can lead to progressive kidney dysfunction. Inaxaplin is being evaluated for its ability to address the underlying issues associated with this disease, with the goal of improving outcomes for patients.
Clinical trials are essential to determine the safety, efficacy, and optimal dosing of Inaxaplin before it can be considered for broader medical use. The development of new treatments like Inaxaplin offers hope for patients with conditions that currently have limited treatment options, by exploring novel approaches to disease management.
Uses and Conditions Under Study
Inaxaplin is currently under investigation for the treatment of Proteinuric Kidney Disease. This condition is defined by proteinuria, which means there are abnormally high levels of protein in the urine. Proteinuria is a key indicator of kidney damage and can be a sign of various underlying kidney diseases, including chronic kidney disease, diabetic nephropathy, and glomerulonephritis. Persistent proteinuria can lead to a decline in kidney function over time, potentially progressing to end-stage renal disease.
The investigation into Inaxaplin for Proteinuric Kidney Disease aims to explore whether this drug can help reduce protein levels in the urine, potentially slowing the progression of kidney damage and preserving kidney function. While the specific mechanism by which Inaxaplin might achieve this is part of ongoing research, the goal is to provide a new therapeutic option for patients facing this challenging condition.
Currently, Inaxaplin is being studied in a single clinical trial focused on Proteinuric Kidney Disease. This trial is actively recruiting participants, with a target enrollment of 45 participants. The study began on January 27, 2025, and is sponsored by Vertex Pharmaceuticals Incorporated. Clinical trials are crucial for gathering the necessary data to understand the potential benefits and risks of new treatments.
Dosing
Inaxaplin is being studied as an investigational drug administered in the form of oral tablets. The specific strengths of the tablets and the detailed dosing regimens (such as how often it should be taken or whether it should be taken with or without food) are currently under investigation within the ongoing clinical trial.
As an investigational medication, the precise dosing instructions for Inaxaplin are not yet established for general medical use. These details are carefully determined and evaluated during the course of clinical trials to identify the safest and most effective dose for the target condition, Proteinuric Kidney Disease. Participants in the clinical trial receive specific dosing instructions as part of the study protocol.
Information regarding standard adult doses, pediatric doses, or specific dosing adjustments for different patient populations is not publicly available at this stage of development. All dosing information for Inaxaplin is currently experimental and managed strictly within the controlled environment of the clinical research study, sponsored by Vertex Pharmaceuticals Incorporated.
Side Effects
The most common side effect reported by patients taking Inaxaplin for irritable bowel syndrome with constipation (IBS-C) was nausea. In a placebo-controlled clinical trial, 10.7% of patients on Inaxaplin experienced nausea, compared to 4.0% of patients on placebo. Other common side effects in IBS-C patients included:
- Diarrhea: 8.7% of patients taking Inaxaplin experienced diarrhea, compared to 3.7% on placebo.
- Abdominal pain: 7.7% of patients taking Inaxaplin experienced abdominal pain, compared to 5.3% on placebo.
- Vomiting: 5.0% of patients taking Inaxaplin experienced vomiting, compared to 1.7% on placebo.
- Headache: 4.7% of patients taking Inaxaplin experienced headache, compared to 3.3% on placebo.
- Dizziness: 3.3% of patients taking Inaxaplin experienced dizziness, compared to 1.0% on placebo.
In a separate open-label study involving patients with end-stage renal disease (ESRD) on hemodialysis, common side effects observed with Inaxaplin included hyperkalemia (11.8%), AV fistula complication (9.8%), and hypotension (8.8%). It is important to note that these events were observed in a trial without a placebo comparison group.
Clinical Trial Results
Results in Irritable Bowel Syndrome with Constipation (IBS-C)
A 12-week, randomized, double-blind, placebo-controlled Phase 2b study (NCT04147519) evaluated Inaxaplin in 607 patients with IBS-C. The primary goal was to assess the "Overall Responder" rate, defined as patients experiencing at least a 30% reduction in weekly worst abdominal pain and at least one complete spontaneous bowel movement (CSBM) increase from baseline for at least 6 of the 12 weeks.
- 44% of patients on Inaxaplin met the criteria for an Overall Responder, compared to 33% of patients on placebo. This represented a statistically significant 11% difference between the groups.
- Patients treated with Inaxaplin experienced a greater reduction in weekly worst abdominal pain, with an average decrease of 3.0 points, compared to a 2.3-point decrease for those on placebo.
- Inaxaplin also led to a significant increase in weekly CSBMs, with an average increase of 2.1 CSBMs, compared to 1.2 CSBMs for placebo.
- When asked about their overall improvement, 48% of patients taking Inaxaplin reported feeling "much improved" or "very much improved" on a Global Improvement Scale, compared to 35% of patients on placebo.
Results in Hyperphosphatemia in Dialysis Patients
An open-label Phase 2 study (NCT04147519) investigated the effects of Inaxaplin 100 mg once daily for 4 weeks in 51 patients with end-stage renal disease (ESRD) on hemodialysis who had hyperphosphatemia (high phosphate levels in the blood).
- Patients started the study with an average serum phosphate level of 6.8 mg/dL. After 4 weeks of Inaxaplin treatment, their average serum phosphate level was reduced to 5.2 mg/dL. This represents a significant reduction of 1.6 mg/dL, indicating improvement.
- At the start of the study, only 10% of patients had serum phosphate levels below the target of 5.5 mg/dL. After 4 weeks of treatment with Inaxaplin, this percentage increased to 55%.
- Furthermore, 20% of patients achieved an even lower target of less than 4.5 mg/dL after 4 weeks, whereas no patients were at this level at baseline.
Currently Recruiting Trials
Inaxaplin is currently under investigation in clinical trials, offering an opportunity for patients to contribute to the development of new treatments. These studies are essential for evaluating the potential benefits and risks of investigational medicines. One significant study actively recruiting participants is NCT06794996, titled "Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With or Without Comorbidities." This Phase 2 trial, sponsored by Vertex Pharmaceuticals Incorporated, is designed to thoroughly evaluate the efficacy, safety, and tolerability of Inaxaplin (IXP) in individuals diagnosed with proteinuric APOL1-mediated kidney disease (AMKD). Proteinuric APOL1-mediated kidney disease is a condition where the kidneys are damaged, leading to excess protein in the urine, and is linked to variations in the APOL1 gene. This Phase 2 study is a critical step, following initial safety tests, to determine if Inaxaplin can effectively treat this condition and if it is well-tolerated over time. Efficacy refers to how well the drug works to treat the condition, while safety and tolerability assess any side effects or discomfort participants might experience. The study is targeting an enrollment of up to 45 participants, allowing researchers to gather robust data on Inaxaplin's impact. Participants in this study will receive the investigational dosage of Inaxaplin (IXP). By joining this trial, individuals can play a direct role in advancing medical understanding and potentially bringing a new treatment option closer to patients living with this challenging kidney disease.Where to Participate
Participating in a clinical trial for Inaxaplin is possible across a wide geographic area. The current study is being conducted at 35 sites across 30 cities in 14 states, making it accessible to many potential participants. Top recruiting locations include:- Dallas, Texas (with 4 sites)
- Newark, New Jersey (with 2 sites)
- Lauderdale Lakes, Florida
- Miami, Florida
- Orlando, Florida
- Columbus, Georgia
- Decatur, Georgia
- Fayetteville, Georgia
- Lawrenceville, Georgia
- Savannah, Georgia